Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in Colombia
To assess cost-effectiveness of conventional cytology and HPV DNA testing for cervical-cancer screening in Colombia. The National Cancer Institute of Colombia (NCIC) in 2007 developed a Markov model on the natural history of cervical cancer; no screening, conventional cytology, and HPV DNA testing w...
Gespeichert in:
| Veröffentlicht in: | Salud pública de México 2008-07, Vol.50 (4), p.276-285 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 285 |
|---|---|
| container_issue | 4 |
| container_start_page | 276 |
| container_title | Salud pública de México |
| container_volume | 50 |
| creator | Andrés-Gamboa, Oscar Chicaíza, Liliana García-Molina, Mario Díaz, Jorge González, Mauricio Murillo, Raúl Ballesteros, Mónica Sánchez, Ricardo |
| description | To assess cost-effectiveness of conventional cytology and HPV DNA testing for cervical-cancer screening in Colombia.
The National Cancer Institute of Colombia (NCIC) in 2007 developed a Markov model on the natural history of cervical cancer; no screening, conventional cytology, and HPV DNA testing were compared. Only direct costs were used. Outcomes comprise cervical cancer mortality, years of life saved, and lifetime costs. Discounted incremental cost-effectiveness ratios were estimated and sensitivity analyses were conducted for key parameters.
Depending on the screening strategy a 69-81% mortality reduction might be expected. The HPV DNA testing every five years is a cost-effective strategy (Incremental Cost-Effectiveness Ratio (ICER): USD$44/YLS) if the cost per test is under USD$31. The effectiveness was sensitive to coverage and primarily to follow-up.
HPV DNA testing is a cost-effective alternative for screening in Colombia. Not only high coverage but high follow-up rates are critical for successful screening programs. |
| doi_str_mv | 10.1590/S0036-36342008000400005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_sciel</sourceid><recordid>TN_cdi_scielo_journals_S0036_36342008000400005</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><scielo_id>S0036_36342008000400005</scielo_id><sourcerecordid>69372742</sourcerecordid><originalsourceid>FETCH-LOGICAL-c399t-4f2889c90e9d34fbfe94cd29782a674ce35af6b7d25749fbfa84fc99b104ddb33</originalsourceid><addsrcrecordid>eNp9UU1PGzEQtVARCWn_AvWpt4VZ27HXxygtHxICJGivK693jIw2dmpvkPLv65CIHpA4jGZG7715mhlCvtdwXs81XDwCcFlxyQUDaABAlID5EZnWEmSldC2_kOk7aUJOc34BYJxxdUImdSMVqLqZEr-MeazQObSjf8WAOdPoqI2hNKOPwQzUbsc4xOctNaGn1w9_6M-7BR0xjz48UxcTtZhevd0xTSg1zTYhhh3qA10W7arz5is5dmbI-O2QZ-T35a-n5XV1e391s1zcVpZrPVbCsabRVgPqngvXOdTC9kyrhhmphEU-N052qmdzJXTBTSOc1bqrQfR9x_mMnO_nZutxiO1L3KSyRW7fbtZ-uFkR_NgL1in-3ZS12pXPFofBBIyb3ErNFVOCFaLaE22KOSd07Tr5lUnbtoZ295ZPLM4OFptuhf1_3eEP_B8xvYbJ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69372742</pqid></control><display><type>article</type><title>Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in Colombia</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EBSCOhost Business Source Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Andrés-Gamboa, Oscar ; Chicaíza, Liliana ; García-Molina, Mario ; Díaz, Jorge ; González, Mauricio ; Murillo, Raúl ; Ballesteros, Mónica ; Sánchez, Ricardo</creator><creatorcontrib>Andrés-Gamboa, Oscar ; Chicaíza, Liliana ; García-Molina, Mario ; Díaz, Jorge ; González, Mauricio ; Murillo, Raúl ; Ballesteros, Mónica ; Sánchez, Ricardo</creatorcontrib><description>To assess cost-effectiveness of conventional cytology and HPV DNA testing for cervical-cancer screening in Colombia.
The National Cancer Institute of Colombia (NCIC) in 2007 developed a Markov model on the natural history of cervical cancer; no screening, conventional cytology, and HPV DNA testing were compared. Only direct costs were used. Outcomes comprise cervical cancer mortality, years of life saved, and lifetime costs. Discounted incremental cost-effectiveness ratios were estimated and sensitivity analyses were conducted for key parameters.
Depending on the screening strategy a 69-81% mortality reduction might be expected. The HPV DNA testing every five years is a cost-effective strategy (Incremental Cost-Effectiveness Ratio (ICER): USD$44/YLS) if the cost per test is under USD$31. The effectiveness was sensitive to coverage and primarily to follow-up.
HPV DNA testing is a cost-effective alternative for screening in Colombia. Not only high coverage but high follow-up rates are critical for successful screening programs.</description><identifier>ISSN: 0036-3634</identifier><identifier>EISSN: 1606-7916</identifier><identifier>DOI: 10.1590/S0036-36342008000400005</identifier><identifier>PMID: 18670718</identifier><language>eng</language><publisher>Mexico: Instituto Nacional de Salud Pública</publisher><subject>Adult ; Aged ; Colombia ; Cost-Benefit Analysis ; DNA Probes, HPV - economics ; Female ; Follow-Up Studies ; Health Policy & Services ; Humans ; Middle Aged ; Uterine Cervical Neoplasms - pathology ; Uterine Cervical Neoplasms - virology</subject><ispartof>Salud pública de México, 2008-07, Vol.50 (4), p.276-285</ispartof><rights>This work is licensed under a Creative Commons Attribution 3.0 International License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c399t-4f2889c90e9d34fbfe94cd29782a674ce35af6b7d25749fbfa84fc99b104ddb33</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,861,882,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18670718$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Andrés-Gamboa, Oscar</creatorcontrib><creatorcontrib>Chicaíza, Liliana</creatorcontrib><creatorcontrib>García-Molina, Mario</creatorcontrib><creatorcontrib>Díaz, Jorge</creatorcontrib><creatorcontrib>González, Mauricio</creatorcontrib><creatorcontrib>Murillo, Raúl</creatorcontrib><creatorcontrib>Ballesteros, Mónica</creatorcontrib><creatorcontrib>Sánchez, Ricardo</creatorcontrib><title>Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in Colombia</title><title>Salud pública de México</title><addtitle>Salud Publica Mex</addtitle><description>To assess cost-effectiveness of conventional cytology and HPV DNA testing for cervical-cancer screening in Colombia.
The National Cancer Institute of Colombia (NCIC) in 2007 developed a Markov model on the natural history of cervical cancer; no screening, conventional cytology, and HPV DNA testing were compared. Only direct costs were used. Outcomes comprise cervical cancer mortality, years of life saved, and lifetime costs. Discounted incremental cost-effectiveness ratios were estimated and sensitivity analyses were conducted for key parameters.
Depending on the screening strategy a 69-81% mortality reduction might be expected. The HPV DNA testing every five years is a cost-effective strategy (Incremental Cost-Effectiveness Ratio (ICER): USD$44/YLS) if the cost per test is under USD$31. The effectiveness was sensitive to coverage and primarily to follow-up.
HPV DNA testing is a cost-effective alternative for screening in Colombia. Not only high coverage but high follow-up rates are critical for successful screening programs.</description><subject>Adult</subject><subject>Aged</subject><subject>Colombia</subject><subject>Cost-Benefit Analysis</subject><subject>DNA Probes, HPV - economics</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Health Policy & Services</subject><subject>Humans</subject><subject>Middle Aged</subject><subject>Uterine Cervical Neoplasms - pathology</subject><subject>Uterine Cervical Neoplasms - virology</subject><issn>0036-3634</issn><issn>1606-7916</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UU1PGzEQtVARCWn_AvWpt4VZ27HXxygtHxICJGivK693jIw2dmpvkPLv65CIHpA4jGZG7715mhlCvtdwXs81XDwCcFlxyQUDaABAlID5EZnWEmSldC2_kOk7aUJOc34BYJxxdUImdSMVqLqZEr-MeazQObSjf8WAOdPoqI2hNKOPwQzUbsc4xOctNaGn1w9_6M-7BR0xjz48UxcTtZhevd0xTSg1zTYhhh3qA10W7arz5is5dmbI-O2QZ-T35a-n5XV1e391s1zcVpZrPVbCsabRVgPqngvXOdTC9kyrhhmphEU-N052qmdzJXTBTSOc1bqrQfR9x_mMnO_nZutxiO1L3KSyRW7fbtZ-uFkR_NgL1in-3ZS12pXPFofBBIyb3ErNFVOCFaLaE22KOSd07Tr5lUnbtoZ295ZPLM4OFptuhf1_3eEP_B8xvYbJ</recordid><startdate>20080701</startdate><enddate>20080701</enddate><creator>Andrés-Gamboa, Oscar</creator><creator>Chicaíza, Liliana</creator><creator>García-Molina, Mario</creator><creator>Díaz, Jorge</creator><creator>González, Mauricio</creator><creator>Murillo, Raúl</creator><creator>Ballesteros, Mónica</creator><creator>Sánchez, Ricardo</creator><general>Instituto Nacional de Salud Pública</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>GPN</scope></search><sort><creationdate>20080701</creationdate><title>Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in Colombia</title><author>Andrés-Gamboa, Oscar ; Chicaíza, Liliana ; García-Molina, Mario ; Díaz, Jorge ; González, Mauricio ; Murillo, Raúl ; Ballesteros, Mónica ; Sánchez, Ricardo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c399t-4f2889c90e9d34fbfe94cd29782a674ce35af6b7d25749fbfa84fc99b104ddb33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Colombia</topic><topic>Cost-Benefit Analysis</topic><topic>DNA Probes, HPV - economics</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Health Policy & Services</topic><topic>Humans</topic><topic>Middle Aged</topic><topic>Uterine Cervical Neoplasms - pathology</topic><topic>Uterine Cervical Neoplasms - virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Andrés-Gamboa, Oscar</creatorcontrib><creatorcontrib>Chicaíza, Liliana</creatorcontrib><creatorcontrib>García-Molina, Mario</creatorcontrib><creatorcontrib>Díaz, Jorge</creatorcontrib><creatorcontrib>González, Mauricio</creatorcontrib><creatorcontrib>Murillo, Raúl</creatorcontrib><creatorcontrib>Ballesteros, Mónica</creatorcontrib><creatorcontrib>Sánchez, Ricardo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SciELO</collection><jtitle>Salud pública de México</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Andrés-Gamboa, Oscar</au><au>Chicaíza, Liliana</au><au>García-Molina, Mario</au><au>Díaz, Jorge</au><au>González, Mauricio</au><au>Murillo, Raúl</au><au>Ballesteros, Mónica</au><au>Sánchez, Ricardo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in Colombia</atitle><jtitle>Salud pública de México</jtitle><addtitle>Salud Publica Mex</addtitle><date>2008-07-01</date><risdate>2008</risdate><volume>50</volume><issue>4</issue><spage>276</spage><epage>285</epage><pages>276-285</pages><issn>0036-3634</issn><eissn>1606-7916</eissn><abstract>To assess cost-effectiveness of conventional cytology and HPV DNA testing for cervical-cancer screening in Colombia.
The National Cancer Institute of Colombia (NCIC) in 2007 developed a Markov model on the natural history of cervical cancer; no screening, conventional cytology, and HPV DNA testing were compared. Only direct costs were used. Outcomes comprise cervical cancer mortality, years of life saved, and lifetime costs. Discounted incremental cost-effectiveness ratios were estimated and sensitivity analyses were conducted for key parameters.
Depending on the screening strategy a 69-81% mortality reduction might be expected. The HPV DNA testing every five years is a cost-effective strategy (Incremental Cost-Effectiveness Ratio (ICER): USD$44/YLS) if the cost per test is under USD$31. The effectiveness was sensitive to coverage and primarily to follow-up.
HPV DNA testing is a cost-effective alternative for screening in Colombia. Not only high coverage but high follow-up rates are critical for successful screening programs.</abstract><cop>Mexico</cop><pub>Instituto Nacional de Salud Pública</pub><pmid>18670718</pmid><doi>10.1590/S0036-36342008000400005</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0036-3634 |
| ispartof | Salud pública de México, 2008-07, Vol.50 (4), p.276-285 |
| issn | 0036-3634 1606-7916 |
| language | eng |
| recordid | cdi_scielo_journals_S0036_36342008000400005 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; EBSCOhost Business Source Complete; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Aged Colombia Cost-Benefit Analysis DNA Probes, HPV - economics Female Follow-Up Studies Health Policy & Services Humans Middle Aged Uterine Cervical Neoplasms - pathology Uterine Cervical Neoplasms - virology |
| title | Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in Colombia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T00%3A18%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_sciel&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost-effectiveness%20of%20conventional%20cytology%20and%20HPV%20DNA%20testing%20for%20cervical%20cancer%20screening%20in%20Colombia&rft.jtitle=Salud%20p%C3%BAblica%20de%20M%C3%A9xico&rft.au=Andr%C3%A9s-Gamboa,%20Oscar&rft.date=2008-07-01&rft.volume=50&rft.issue=4&rft.spage=276&rft.epage=285&rft.pages=276-285&rft.issn=0036-3634&rft.eissn=1606-7916&rft_id=info:doi/10.1590/S0036-36342008000400005&rft_dat=%3Cproquest_sciel%3E69372742%3C/proquest_sciel%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69372742&rft_id=info:pmid/18670718&rft_scielo_id=S0036_36342008000400005&rfr_iscdi=true |